News

Jill Winther earned the 2026 Extraordinary Healer® Award for her leadership, advocacy and dedication to oncology nursing.

The FDA approved oral decitabine/cedazuridine and venetoclax for AML. Research showed a 41.6% complete remission rate in chemo-ineligible adults

The FDA approved sonrotoclax for R/R mantle cell lymphoma. Nurses must manage a 4-week dose ramp-up to prevent TLS for patients after prior BTK therapy.

A new survey reveals 53% of rural cancer patients struggle with costs, highlighting urgent needs for patient navigation and policy reform.

Experts warn of "molecular anxiety" and financial toxicity as ctDNA testing enters early-stage breast cancer surveillance.

New research identifies a significant link between immune checkpoint inhibitors and peripheral artery disease, prompting a need for nurse monitoring.

MD Anderson’s trial uses psilocybin to help oncology patients overcome anxiety and depression during maintenance therapy.

Learn about the FDA approval of vepdegestrant (Veppanu), the first PROTAC for ESR1-mutated breast cancer, including nursing priorities and side effects.

FDA approved zenocutuzumab-zbco for post-systemic-therapy, NRG1 fusion–positive unresectable/metastatic cholangiocarcinoma, addressing an ultra-rare molecular subset with limited options.

Dr. Jennifer Bickel said system-level wellness supports care teams, improving patient safety, experience and outcomes in oncology care.

Gedatolisib Improves Progression-Free Survival in PIK3CA-Mutant HR+/HER2- Metastatic Breast Cancer Versus Alpelisib Combination Therapy

FDA approved Veppanu for ER+, HER2- ESR1-mutated breast cancer after endocrine therapy, improving PFS to 5 months vs 2.1 and reducing progression risk by 43%.

Dr. Mutahar Ahmed of John Theurer Cancer Center highlights nurses’ vital role in bladder cancer care, supporting patients through treatment and recovery

FDA approves vepdegestrant for ER-positive, HER2-negative breast cancer. Learn key efficacy data, safety risks, and nursing care considerations.

Phase 3 MagnetisMM-5 trial data in multiple myeloma highlight progression-free survival gains and key safety considerations for oncology nurses.

Paget disease of the breast: key signs, diagnosis, and treatment strategies oncology nurses should know to support early detection and patient care.

Oncology nurse practitioners discuss CD38-based frontline therapy for newly diagnosed multiple myeloma, including Dara-VRd efficacy, AE management, and subcutaneous administration strategies.

Oncology nurses play key role in guiding patients with non-small cell lung cancer on KRAS therapies and emerging options.

FDA accepts Zanidatamab combo sBLA for HER2+ gastroesophageal cancer, showing improved outcomes in HERIZON-GEA-01 trial with priority review underway.

Catherine Boyles, RN, provides an overview of fertility preservation in young cancer patients and the role of oncology nurses.

FDA grants fast track designation to lunresertib plus zedoresertib for genomic-defined platinum-resistant ovarian cancer following phase 1 data.

Consistent assessment and follow-up help manage low-grade irAEs, with continued monitoring and coordination supporting long-term toxicity care.

Workforce shortages, delayed diagnoses, and systemic barriers continue to limit cancer care delivery in low-resource settings, experts report.

Ozekibart plus FOLFIRI demonstrated a 20% response rate and 5.5-month progression-free survival in heavily pretreated colorectal cancer.

LITESPARK-012 failed to improve OS or PFS in advanced renal cell carcinoma, reinforcing pembrolizumab plus lenvatinib as a first-line standard.

FDA grants Priority Review to enfortumab vedotin plus pembrolizumab in MIBC, showing improved survival and reduced recurrence risk in phase 3 EV-304 trial.